Manuscript no. HAEMATOL/2011/044115 entitled "The NOTCH pathway contributes to cell fate decisions in myelopoiesis"

Authors: Laurence Bugeon, Harriet B. Taylor, Fränze Progatzky, Michelle I. Lin, Charles D. Ellis, Natalie Welsh, Emma Smith, Neil Vargesson, Caroline Gray, Stephen A. Renshaw, Timothy J. A. Chico, Leonard I. Zon, Jonathan Lamb, and Margaret J. Dallman

Information about the contributions of each person named as having participated in the study

- 1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
- Margaret Dallman, Imperial College London, m.dallman@imperial.ac.uk
- Jonathan Lamb, Imperial College London, jonathan.lamb@imperial.ac.uk

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

- 2) Authors who participated in the conception of the study: Laurence Bugeon, Harriet Taylor, Charles Ellis, Emma Smith, Leonard Zon, Jonathan Lamb, Margaret Dallman
- 3) Design & Methods. The following authors were responsible for specific investigations (please detail):
- Laurence Bugeon was responsible for the Flow cytometry analysis of the adult
- Harriet Taylor was responsible for the tail transection experiment and morpholino experiments
- Franze Progatzky was responsible for the flow cytometry of the embryos
- Charles Ellis was responsible for the genotyping and flow cytometry
- Emma Smith was responsible for the flow cytometry experiments
- Natalie Welsh was responsible for the gene expression analysis
- Michelle Lin was responsible for the in situ experiment
- Neil Vargesson, Timothy Chico, Caroline Gray and Stephen Renshaw were responsible for producing/supplying the mutant/transgenic fish
- 4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
- Laurence Bugeon was responsible for Figure 4, 5 and 6
- Harriet Taylor was responsible for figure 2 & 4
- Franze Progatzky was responsible for figure 2 & 3
- Charles Ellis was responsible for figure 5 & 6
- Emma Smith was responsible for figure 5 & 6
- Natalie Welsh was responsible for figure 4E
- Michelle Lin was responsible for figure 1

All studies were made possible by the provision of transgenic/mutant fish by Neil Vargesson, Timothy Chico, Caroline Gray and Stephen Renshaw

- 5) Writing the manuscript. The following authors were responsible for writing the manuscript:
- Laurence Bugeon wrote the manuscript draft which was revised by all authors and in particular by Margaret Dallman
- 6) Contributors Listed in Acknowledgments: (Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Corresponding authors must declare whether they had assistance with the study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors must disclose the identity of the individuals who provided this assistance and the entity that supported it. Financial and material support should also be acknowledged.)

Cristina Lo Celso for critical reading of the manuscript. LIZ is a founder and stock holder of Fate, Inc. and a scientific advisor for Stemgent. Funding: this work was supported by GlaxoSmithKline and the MRC.